Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pitching A Stent Amid The Hype: Cypher, Taxus Programs In 2003 And Beyond

This article was originally published in The Gray Sheet

Executive Summary

Patient and physician demand for drug-eluting stents in the U.S. has played an inimitable role in shaping the cardiovascular device market over the past year - and has set the stage for a stirring competition between the Cypher and Taxus stents

You may also be interested in...



Eye Care Firms Ride New Products, Overseas Growth To Fuel Stocks In 2004

Contact lens manufacturers The Cooper Companies and Bausch & Lomb are taking aim at the Asian specialty lens market to sustain growth experienced in 2003, following a rebound in stock prices for ophthalmic device manufacturers after a two-year lull

Eye Care Firms Ride New Products, Overseas Growth To Fuel Stocks In 2004

Contact lens manufacturers The Cooper Companies and Bausch & Lomb are taking aim at the Asian specialty lens market to sustain growth experienced in 2003, following a rebound in stock prices for ophthalmic device manufacturers after a two-year lull

Taxus Clears Legal Hurdle As Judge Denies J&J/Cordis Injunction Request

The arguments made by Boston Scientific and Johnson & Johnson/Cordis in the ongoing drug-eluting stent patent dispute both have merit, according to Wilmington, Del. federal court Judge Sue Robinson

Related Content

UsernamePublicRestriction

Register

MT019541

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel